ChromaDex

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ChromaDex reports record revenue and eyes growth through partnerships

ChromaDex's strong revenue growth and positive EBITDA reflect operational improvements.
The company faces challenges in sales channels and marketing claims but sees growth opportunities.
Strategic focus on new partnerships, product development, and pharmaceutical initiatives for future growth.

ChromaDex reports robust Q1 performance, eyes innovation for growth

ChromaDex's Q1 2023 performance was strong, with notable growth in revenue and positive cash flows. The company faces challenges in recurring revenue conversion and aims for improved financial metrics. However, opportunities lie in innovation, R&D, and potential partnerships for future growth.

ChromaDex reports strong Q2 earnings and eyes market expansion

ChromaDex's Q2 performance reflects robust revenue growth, strong partnerships, and a commitment to scientific excellence, positioning the company for continued success.
While facing challenges such as customer retention and working capital management, ChromaDex remains focused on profitability and strategic investments for future growth.
Opportunities in expanding market share, leveraging key partnerships, and enhancing customer loyalty present avenues for sustained revenue growth and market leadership.
With a solid financial position and a balanced approach to growth, ChromaDex is poised to navigate challenges and capitalize on opportunities in the evolving market landscape.

ChromaDex reports robust Q3 results, eyes growth through strategic partnerships

ChromaDex's Q3 performance reflects revenue growth, profitability, and operational efficiency, supported by strong financials and strategic partnerships.
The company's focus on innovation, market expansion, and cost control measures positions it well for sustained growth and competitive advantage.
While facing challenges in a dynamic market environment, ChromaDex's opportunities lie in product innovation, market diversification, and strategic partnerships.
Overall, ChromaDex's strategic initiatives and financial strength indicate a positive outlook for future growth and market expansion.

ChromaDex reports robust earnings, eyes growth through partnerships and innovation

ChromaDex delivered strong financial performance in Q4 2023 and full year 2023, driven by revenue growth, partnerships, and product demand.
While facing challenges in meeting consumer demand and optimizing resource allocation, the company remains focused on responsible practices and future growth opportunities.
With a solid financial foundation, strategic partnerships, and a focus on innovation, ChromaDex is poised for continued growth and market leadership in the dietary supplement industry.

ChromaDex reports revenue growth and strategic partnerships for future expansion

ChromaDex's Q1 2024 performance reflects revenue growth, positive EBITDA, and strategic initiatives for future expansion.
The company's strengths lie in subscriber base building, successful product SKUs, and stable market presence in key segments.
While facing challenges such as increased expenses and short-term R&D investments, ChromaDex is well-positioned for growth.
Opportunities in new partnerships, product development, and market exploration offer avenues for revenue growth and enhanced customer value.

ChromaDex reports revenue growth and product innovation in Q2

ChromaDex's Q2 2024 performance showed revenue growth, positive EBITDA, and a strong cash position.
The company's strengths lie in its innovative NIAGEN product line and positive clinical study outcomes.
Challenges include market misinformation and the need to adjust outlook due to product delays.
Opportunities exist in addressing specific health conditions and leveraging marketing strategies for growth.

ChromaDex (CDXC) reports record Q3 results and eyes growth

ChromaDex (CDXC) delivers strong Q3 performance with record revenue and profitability, driven by e-commerce and product launches.
Despite challenges in outlook adjustment and pricing strategies, the company's financial discipline and market focus position it for growth.
Opportunities lie in expanding product reach, FDA approvals, and strategic marketing to capitalize on market potential.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m.

ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that its consumer nicotinamide adenine dinucleotide (NAD+) boosting supplement, Tru Niagen®, won the “Most Popular Brand of the Year Award” at Asia's largest trade show on natural health and nutrition products, China International Natural Health & Nutrition Expo (NHNE), during the prestigious Nutrition Planet Awards on September 20, 2022 in Shanghai.

ChromaDex's Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo's (NHNE) Prestigious Nutrition Planet Awards

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #niagen--ChromaDex Corp. (NASDAQ:CDXC) (“the Company” or “ChromaDex”) a global bioscience company dedicated to healthy aging, announced today a new long term commercial license and supply agreement with Nestlé Health Science, a global leader in science-based nutritional health solutions. The new agreement expands the previous supply agreement executed in 2018 to include dietary supplements. The agreement provides Nestlé Health Science the non-exclusive right to manufacture,

ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CERP--ChromaDex Corp. (NASDAQ:CDXC) today announced promising findings from a clinical study, as reported in the peer-reviewed journal Journal of the American College of Cardiology (JACC): Basic to Translational Science by a team of scientists led by Dr. Kevin O'Brien, Division of Cardiology, Department of Medicine, in collaboration with Dr. Rong Tian, Mitochondria and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington School of M

ChromaDex Shares Promising Findings from Clinical Study Showcasing ​​the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (the “Company”), a global bioscience company dedicated to healthy aging, today announced that it has established a joint venture through its wholly owned subsidiary ChromaDex Asia Pacific Ventures Limited (the “JV” or “ChromaDex Asia”). The JV collectively consists of the Company and Hong Kong Taikuk (China) Group Limited. The purpose of the JV will be to commercialize Tru Niagen® and other products containing Niagen® in China. ChromaD

ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) today announced that Sinopharm Xingsha will debut Tru Niagen® at the major mainland China trade show, China International Natural Health & Nutrition Expo (NHNE), which kicks off Tuesday, September 20, in Shanghai. NHNE is Asia's largest expo on natural health and nutrition products, with over 100,000 distributors and retailers. It is considered the best platform to help global manufacturers of health food and nutrition promote thei

Sinopharm Xingsha to Introduce ChromaDex's Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #HCPbrazil--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with MyPharma2Go to conduct cross-border sales of Tru Niagen® and Tru Niagen® PRO in Brazil, the first Latin American country to welcome the brand. Nicotinamide riboside or NR, the key ingredient in Tru Niagen®, is the world's most efficient nicotinamide adenine dinucleotide (NAD+) precursor on the market, particularly over NMN (nicotinamide mononucleotide). MyPharma2Go, an American company focused on Braz

ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil

Ginkgo Bioworks Holdings

Health and wellness industry veteran will lead the company to scale sustainable bioactives using plant cell technology instead of agriculture                                                      BOSTON , Aug. 24, 2022 /PRNewswire/ -- Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the appointment of Frank Jaksch as the company's chief executive officer. Jaksch founded, was the longtime CEO and presently serves as Board Chair of health and wellness company ChromaDex, manufacturer of popular NAD product, Tru Niagen (Nasdaq: CDXC).

Ayana Bio Announces Appointment of Frank Jaksch as Chief Executive Officer

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced the U.S. Patent & Trademark Office's Patent Trial and Appeal Board's (“PTAB”) decision to reject Thorne Research, Inc. attempt to invalidate U.S. Patent No. 8,197,807 (“the 807 patent”). ChromaDex holds an exclusive license to the 807 patent for compositions including nicotinamide riboside (NR) from the Trustees of Dartmouth College. The decision, if

Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex's Intellectual Property Held Under Exclusive License From Dartmouth College

ChromaDex Corporation (NASDAQ:CDXC ) Q2 2022 Results Conference Call August 10, 2022 4:30 AM ET Company Participants Heather Van Blarcom - Senior Vice President of Legal and Corporate Secretary Robert Fried - Chief Executive Officer Kevin Farr - Chief Financial Officer Brianna Gerber - Vice President of Finance and Investor Relations Conference Call Participants Brian Nagel - Oppenheimer Mitchell Pinheiro - Sturdivant Raghuram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital Jeffrey Cohen - Ladenburg Thalmann Jeff Van Sinderen - B.

ChromaDex Corporation (CDXC) CEO Robert Fried on Q2 2022 Results - Earnings Call Transcript

ChromaDex (CDXC) delivered earnings and revenue surprises of -12.50% and 8.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q2 Loss, Lags Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2022. Second Quarter 2022 and Recent Highlights Total net sales were $16.7 million, with $14.5 million from Tru Niagen®, down 5% and 6% from the prior year period, respectively. Total net sales and Tru Niagen® net sales remained relatively flat year over year excluding the initial shelf stocking sales to Wal-Mart in the second quarter of 2021. Sales were also impacted by the t

ChromaDex Corporation Reports Second Quarter 2022 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss its financial results for the second quarter, which ended June 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex management will host an investor conference call to discuss the second quarter re

ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #DrCharlesBrenner--ChromaDex Corp. (NASDAQ:CDXC) today announced that it will host a key opinion leader (KOL) webinar on the transforming benefits of nicotinamide riboside (NR) on Wednesday, July 20, 2022 at 11:00 am Eastern Time. The webinar will feature a presentation from KOL and discoverer of the vitamin activity of NR, Dr. Charles Brenner, Alfred E Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and ChromaDex Chief Scientifi

ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ASN--ChromaDex Corp. (NASDAQ:CDXC) today announced that members of its team, a Scientific Advisory Board member and two ChromaDex External Research Program (CERP™) investigators, will be presenting at several key scientific conferences including the American Society for Nutrition's (ASN) Nutrition 2022, the International Society of Sports Nutrition (ISSN) annual meeting, and Federation of American Societies for Experimental Biology (FASEB), The NAD+ Metabolism and Signa

ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced a signed distribution agreement with Sinopharm Xingsha to accelerate cross-border sales of Tru Niagen® into mainland China. Tru Niagen® features ChromaDex's proprietary Niagen® (patented nicotinamide riboside or NR) ingredient, which is the world's most efficient NAD+ (nicotinamide adenine dinucleotide) precursor on the market, particularly over NMN

ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Oppenheimer--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting at Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference. The ChromaDex management team is scheduled to present virtually on Wednesday, June 15th at 3:45 p.m. Eastern Time (12:45 p.m. Pacific Time). ChromaDex management will also attend virtual one-on-one meetings with institutional investors throughout

ChromaDex to Present at the Oppenheimer's 22nd Annual Consumer Growth and E-Commerce Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) today announced a partnership with Juvenis to conduct cross-border sales of Tru Niagen® in South Korea. Juvenis is a Korean healthcare marketing company with a focus on the cosmetic and dietary supplement industries. With strong partnerships in a dynamic and trend-setting Korean market, Juvenis emphasizes products with differentiated science and proven benefits. Tru Niagen® is one of Amazon's top-selling brands in the Vitamin B3 catego

ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #LDMicro--ChromaDex Corp. (NASDAQ:CDXC) today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Kevin Farr, will be presenting virtually at the 12th annual Invitational. This three-day investor conference is expected to feature around 200+ companies. The ChromaDex management team is scheduled to present on Wednesday, June 8th at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) at the Four Seasons Westlake Village. ChromaDex management will al

ChromaDex to Present at the LD Micro Invitational

ChromaDex Corp (NASDAQ: CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited.  ChromaDex Asia is expected to assume the distribution agreement with Sinopharm Xingsha relating to the commercialization of Tru.

ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the “JV Agreement”) to establish a joint venture through its wholly owned subsidiary ChromaDex Asia Limited (the “JV” or “ChromaDex Asia”). Upon establishment of the JV, membership of ChromaDex Asia will collectively consist of the Company; Crystal Lake Developments Limited; Pioneer Idea Holdings Limited; and Hong K

ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERPTM) with a 2022 European NutraIngredients Award in the “Nutrition Research Project” category for developing the science behind ChromaDex's proprietary and patented Niagen® nicotinamide riboside (NR) ingredient. Niagen is an efficient precursor for the essential cellular coenzyme nicotina

ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®

ChromaDex Corporation (NASDAQ:CDXC ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Rob Fried – Chief Executive Officer Kevin Farr – Chief Financial Officer Brianna Gerber – Vice President of Finance, Investor Relation Frank Jaksch – Co-Founder and Executive Chairman Conference Call Participants Brian W. Nagel – Oppenheimer & Co. Mitchell Pinheiro – Sturdivant & Co. Sean McGowan – ROTH Capital Partners Bill Dezellem – Tieton Capital Management Operator Ladies and gentlemen, thank you for standing by, and welcome to ChromaDex Corporation's, first quarter 2022 Earnings Conference Call.

ChromaDex Corporation (CDXC) CEO Rob Fried on Q1 2022 Results - Earnings Call Transcript

ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2022. First Quarter 2022 and Recent Highlights Total net sales were $17.3 million, up 18% from the prior year quarter. Tru Niagen® net sales were $14.9 million, a 20% increase from the prior year quarter. In April 2022, the ChromaDex External Research Program (CERP) achieved its 250th material transfer agreement since 2013, resulting in over 100 peer-reviewed preclinical and cl

News for ChromaDex Stock (CDXC)